Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sharla Chenoweth"'
Autor:
Michael J. Reardon, Sandeep M. Patel, Marco A. Costa, Paul Sorajja, Sharla Chenoweth, Guilherme F. Attizzani, George Dangas, Wilson Y. Szeto, Jeffrey J. Popma, Susheel Kodali
Publikováno v:
The American Journal of Cardiology. 123:419-425
Transfemoral transcatheter aortic valve replacement (TF-TAVR) is mostly performed under general anesthesia (GA) in most US centers. We examined in-hospital and 30-day outcomes in patients who underwent TF-TAVR with a self-expanding bioprosthesis usin
Autor:
Stanley Chetcuti, Susheel Kodali, Jeffrey J. Popma, Wilson Y. Szeto, Paul Sorajja, David H. Adams, Sharla Chenoweth, Michael J. Reardon, James B. Hermiller
Publikováno v:
JACC: Cardiovascular Interventions. 10:2090-2098
Objectives The authors sought to compare the outcomes of commercial transcatheter aortic valve replacement (TAVR) with the repositionable Evolut R platform to those observed with the CoreValve device in the Society of Thoracic Surgeons (STS)/American
Autor:
Thomas G. Gleason, G. Chad Hughes, David H. Adams, Sharla Chenoweth, Jeffrey J. Popma, G. Michael Deeb, Michael J. Reardon, John V. Conte, Louis R. Caplan, Neal S. Kleiman, John Schindler
Publikováno v:
The Journal of Thoracic and Cardiovascular Surgery. 152:85-96
Objectives This study was designed to characterize the incidence of new clinically detectable neurologic events, or any comparative change in indices of higher cognitive function following transcatheter aortic valve replacement (TAVR) or surgical aor
Autor:
Paul, Sorajja, Susheel, Kodali, Michael J, Reardon, Wilson Y, Szeto, Stanley J, Chetcuti, James, Hermiller, Sharla, Chenoweth, David H, Adams, Jeffrey J, Popma
Publikováno v:
JACC. Cardiovascular interventions. 10(20)
The authors sought to compare the outcomes of commercial transcatheter aortic valve replacement (TAVR) with the repositionable Evolut R platform to those observed with the CoreValve device in the Society of Thoracic Surgeons (STS)/American College of
Autor:
David H, Adams, Jeffrey J, Popma, Michael J, Reardon, Steven J, Yakubov, Joseph S, Coselli, G Michael, Deeb, Thomas G, Gleason, Maurice, Buchbinder, James, Hermiller, Neal S, Kleiman, Stan, Chetcuti, John, Heiser, William, Merhi, George, Zorn, Peter, Tadros, Newell, Robinson, George, Petrossian, G Chad, Hughes, J Kevin, Harrison, John, Conte, Brijeshwar, Maini, Mubashir, Mumtaz, Sharla, Chenoweth, Jae K, Oh, Jean-Claude, Laborde
Publikováno v:
New England Journal of Medicine. 370:1790-1798
BACKGROUND We compared transcatheter aortic-valve replacement (TAVR), using a self-expanding transcatheter aortic-valve bioprosthesis, with surgical aortic-valve replacement in patients with severe aortic stenosis and an increased risk of death durin
Autor:
Jeffrey J, Popma, David H, Adams, Michael J, Reardon, Steven J, Yakubov, Neal S, Kleiman, David, Heimansohn, James, Hermiller, G Chad, Hughes, J Kevin, Harrison, Joseph, Coselli, Jose, Diez, Ali, Kafi, Theodore, Schreiber, Thomas G, Gleason, John, Conte, Maurice, Buchbinder, G Michael, Deeb, Blasé, Carabello, Patrick W, Serruys, Sharla, Chenoweth, Jae K, Oh, Lisa, Hermann
Publikováno v:
Journal of the American College of Cardiology, 63(19), 1972-1981. Elsevier Inc.
Objectives This study sought to evaluate the safety and efficacy of the CoreValve transcatheter heart valve (THV) for the treatment of severe aortic stenosis in patients at extreme risk for surgery. Background Untreated severe aortic stenosis is a pr
Autor:
Michael J, Reardon, David H, Adams, Joseph S, Coselli, G Michael, Deeb, Neal S, Kleiman, Stan, Chetcuti, Steven J, Yakubov, David, Heimansohn, James, Hermiller, G Chad, Hughes, J Kevin, Harrison, Kamal, Khabbaz, Peter, Tadros, George L, Zorn, William, Merhi, John, Heiser, George, Petrossian, Newell, Robinson, Brijeshwar, Maini, Mubashir, Mumtaz, Joon Sup, Lee, Thomas G, Gleason, Jon, Resar, John, Conte, Daniel, Watson, Sharla, Chenoweth, Jeffrey J, Popma, Jean-Claude, Laborde
Publikováno v:
The Journal of Thoracic and Cardiovascular Surgery. (6):2869-2876.e7
Objectives The CoreValve Extreme Risk US Pivotal Trial enrolled patients with symptomatic severe aortic stenosis deemed unsuitable for surgical aortic valve replacement. Implants were attempted using transfemoral access (n = 489) or an alternative ac